Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

EU Regulator: Morning-After Pill OK for All Women

By R&D Editors | July 24, 2014

A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer’s declaration that the drugs didn’t work in women weighing more than 80 kilograms (176 pounds).
 
Last November, HRA Pharma changed the labels on its morning-after pill Norlevo, marketed in 50 countries, saying it was ineffective in women over 80 kilograms after a study of levonorgestrel, one of the drug’s active ingredients. Norlevo is not sold in the U.S. but another drug with the same main ingredient, Plan B One-Step, is widely available. The Food and Drug Administration said last year it was reviewing the issue to see if any label changes were needed.
 
In a statement on Thursday, the EMA said it had assessed all the available evidence and announced the data “are too limited and not robust enough to conclude with certainty” that the pill’s efficacy is reduced in heavier women. It said the results of these studies should be included in the product information but that current warnings on Norlevo’s packaging should be deleted.
 
The morning-after pill contains a higher dose of the hormone in regular birth control pills. Taking it within 72 hours of sexual intercourse can cut the chances of pregnancy by up to 89 percent but it works best within the first 24 hours. If a woman is already pregnant, the pill, which prevents ovulation or fertilization, has no effect.
 
Date: July 24, 2014
Source: Associated Press

Related Articles Read More >

Who’s building in pharma, and who would be spared from 100% tariffs, if enacted
2025 R&D layoffs tracker: hardware and chips lead the year’s biggest cuts while biopharma pares pipelines
Skin’s built-in “stretch sensor” helps tissue grow in mouse study
Meissner launches rotary impeller mixing solutions (RMS) portfolio for biocontainer mixing
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2025 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

R&D 100 Awards
Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE